GLYC Stock Overview
A biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
GlycoMimetics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.30 |
52 Week High | US$3.53 |
52 Week Low | US$0.26 |
Beta | 2.29 |
1 Month Change | -84.45% |
3 Month Change | -90.70% |
1 Year Change | -84.88% |
3 Year Change | -88.12% |
5 Year Change | -97.45% |
Change since IPO | -96.68% |
Recent News & Updates
Recent updates
GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Jan 30Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Nov 19Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?
Jan 30Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely
Oct 06GlycoMimetics has a new Chief Medical Officer
Sep 06GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K
Aug 03GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely
Jun 04GlycoMimetics Positive Data For AML Therapy Increasingly Likely
Mar 16Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Nov 20We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully
Aug 20GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study
May 26Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year
May 12GlycoMimetics EPS beats by $0.04
May 03Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Mar 26GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares
Feb 19GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings
Jan 24How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?
Dec 28New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease
Dec 07Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Dec 07The Investment Case For GlycoMimetics
Nov 17Shareholder Returns
GLYC | US Biotechs | US Market | |
---|---|---|---|
7D | 12.3% | 3.2% | 1.7% |
1Y | -84.9% | 6.2% | 26.3% |
Return vs Industry: GLYC underperformed the US Biotechs industry which returned 6% over the past year.
Return vs Market: GLYC underperformed the US Market which returned 26.3% over the past year.
Price Volatility
GLYC volatility | |
---|---|
GLYC Average Weekly Movement | 26.1% |
Biotechs Industry Average Movement | 11.1% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: GLYC's share price has been volatile over the past 3 months.
Volatility Over Time: GLYC's weekly volatility has increased from 16% to 26% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 35 | Harout Semerjian | www.glycomimetics.com |
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein.
GlycoMimetics, Inc. Fundamentals Summary
GLYC fundamental statistics | |
---|---|
Market cap | US$19.30m |
Earnings (TTM) | -US$37.28m |
Revenue (TTM) | US$10.00k |
1,930x
P/S Ratio-0.5x
P/E RatioIs GLYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GLYC income statement (TTM) | |
---|---|
Revenue | US$10.00k |
Cost of Revenue | US$0 |
Gross Profit | US$10.00k |
Other Expenses | US$37.29m |
Earnings | -US$37.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.58 |
Gross Margin | 100.00% |
Net Profit Margin | -372,767.37% |
Debt/Equity Ratio | 0% |
How did GLYC perform over the long term?
See historical performance and comparison